Development of Specific Antibodies to an ARF Protein in Treated Patients with Chronic HCV Infection

2007 ◽  
Vol 52 (9) ◽  
pp. 2427-2432 ◽  
Author(s):  
Michal Cohen ◽  
Larisa Bachmatov ◽  
Ziv Ben-Ari ◽  
Yaron Rotman ◽  
Ran Tur-Kaspa ◽  
...  
2001 ◽  
Vol 120 (5) ◽  
pp. A567-A567 ◽  
Author(s):  
E JAECKEL ◽  
M CORNBERG ◽  
T SANTANTONIO ◽  
J MAYER ◽  
H WEDEMEYER ◽  
...  

2008 ◽  
Vol 46 (01) ◽  
Author(s):  
N Semmo ◽  
M Müller ◽  
C Neumann-Haefelin ◽  
HC Spangenberg ◽  
HE Blum ◽  
...  

2020 ◽  
pp. 79-82
Author(s):  
Nataliia Volodymyrivna Shepylieva ◽  
Alla Oleksandrivna Shvaichenko

A global problem for humanity is the wide spread of HCV carriers worldwide. To address this, the WHO has developed a global strategy for the health sector to eliminate viral hepatitis and has set the following goals: to reduce the number of new cases of chronic hepatitis B and C by 90 % by 2030 as well as to reduce the quantity of death from these infections by 65 %. It is emphasized that the development of infectious or somatic disease on the background of chronic viral hepatitis requires a more careful approach and thorough medical correction, as their course and prognosis can be significantly aggravated. The case of viral hepatitis A, which occurred on a background of previously undiagnosed HCV infection and resulted in a death, has been described. Thus, previously undiagnosed HCV infection exacerbated the course of a self−eliminating disease, such as hepatitis A, and resulted in a death. Therefore, expanding the screening for viral hepatitis will allow identifying infected individuals and conducting antiviral therapy and preventive measures, which will reduce the incidence and mortality rates. Key words: viral hepatitis A, viral hepatitis C, chronic HCV−infection, diagnosis, treatment, outcome.


Sign in / Sign up

Export Citation Format

Share Document